Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Innova Captab Ltd (INNOVACAP) is currently trading at 941.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Innova Captab Limited is an integrated pharmaceutical company engaged in CDMO services, as well as domestic and international branded generics. It operates comprehensive manufacturing units producing various dosage forms across multiple therapeutic areas. The company has shown a robust financial performance with a 42% YoY revenue growth in Q3 FY26, driven by accelerated expansion in both CDMO and branded generics sectors, particularly with substantial contributions from its Jammu facility. Innova Captab's manufacturing capabilities are bolstered by recent certifications including UK-MHRA for its Baddi facility and PIC/s for its Jammu facility, aligning with global standards for quality pharmaceuticals production. The company is strategically focusing on expanding its geographic reach, demonstrated by exports constituting 35% of their revenue in Q3 FY26, showcasing their increasing presence in the global market. Recent capacity expansions and greenfield projects in Jammu are part of the company's aggressive growth strategy, aiming for increased production capacity and operational scale in the coming years.
Over the past 52 weeks, Innova Captab Ltd has traded between a low of ₹608.25 and a high of ₹1,002.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Innova Captab Ltd has a market capitalization of approximately 5,443.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Innova Captab Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 38.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,443.52 Cr, Innova Captab Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Innova Captab Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Innova Captab Ltd is 38.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
204.00 | 6,620 Cr | 4.26 | 4.94 | 0.00 | 116.01 | 80.89 | 71.55 | ||
378.25 | 6,158 Cr | 21.88 | 2.48 | 1.32 | 11.32 | 15.18 | 9.64 | ||
621.85 | 5,637 Cr | 30.22 | 2.65 | 0.56 | 8.22 | 9.59 | 5.36 | ||
943.65 | 5,444 Cr | 38.63 | 4.99 | 0.21 | 12.92 | 14.30 | 7.67 | ||
1159.60 | 5,340 Cr | 46.29 | 5.72 | 0.00 | 12.36 | 14.43 | 7.58 | ||
436.05 | 4,613 Cr | 35.72 | 3.87 | 0.23 | 10.82 | 16.48 | 9.03 | ||
835.80 | 4,324 Cr | 212.36 | 3.36 | 0.00 | 2.11 | 2.48 | 1.10 | ||
| Median: 7 Co. | — | 621.85 | 5,444 Cr | 35.72 | 3.87 | 0.21 | 11.32 | 14.43 | 7.67 |
Bearish
8
Neutral
2
Bullish
4
Bearish
9
Neutral
2
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Innova Captab Limited is an integrated pharmaceutical company engaged in CDMO services, as well as domestic and international branded generics. It operates comprehensive manufacturing units producing various dosage forms across multiple therapeutic areas.
The company has shown a robust financial performance with a 42% YoY revenue growth in Q3 FY26, driven by accelerated expansion in both CDMO and branded generics sectors, particularly with substantial contributions from its Jammu facility.
Innova Captab's manufacturing capabilities are bolstered by recent certifications including UK-MHRA for its Baddi facility and PIC/s for its Jammu facility, aligning with global standards for quality pharmaceuticals production.
The company is strategically focusing on expanding its geographic reach, demonstrated by exports constituting 35% of their revenue in Q3 FY26, showcasing their increasing presence in the global market.
Recent capacity expansions and greenfield projects in Jammu are part of the company's aggressive growth strategy, aiming for increased production capacity and operational scale in the coming years.
Pharmaceuticals & Biotechnology
Pharmaceuticals
5,385 Cr
Low Risk
38.2
34.1
1.1
5.0
1,002.95
608.25
Sales CAGR
Profit CAGR
ROE
ROCE
